BeOne Medicines (ONC) Jefferies London Healthcare Conference 2025 summary

Strategic platform and infrastructure

• Built a proprietary global infrastructure with 6,000 staff, enabling rapid, cost-effective clinical trials in 40–50 countries and direct data collection without heavy reliance on third parties.

• Achieved significant R&D productivity, advancing 16 new molecular entities into the clinic in two years, with expectations for continued growth.

• Maintains a broad pipeline across small molecules, degraders, ADCs, and biologics, with strong internal manufacturing capabilities supporting rapid development.

• Focuses on modalities with high internal expertise, notably protein degradation and biologics, while deprioritizing areas like CAR-T and gene therapy.

Financial and global expansion

• Over 50% of revenue is generated in the U.S., with European sales growing 71% year-over-year and rest-of-world sales up 133% in Q3; Japan recently launched.

• Manufacturing investments include an $800 million biologics facility in New Jersey, supporting global supply for key products.

• Achieved profitability and strong cash flow, with $125 million net income and $354 million free cash flow in Q3, supporting ongoing R&D and business development.

CLL franchise and clinical strategy

• CLL vision is to provide optimal treatment for all patient subtypes and stages, anchored by BRUKINSA, the leading global BTK inhibitor.

• Six-year data for BRUKINSA shows 74% milestone PFS, outperforming other BTK monotherapies; head-to-head trials confirm superiority.

• BCL2 inhibitor Sonrotoclax demonstrates faster, deeper MRD negativity than existing combinations, with broad efficacy across CLL subtypes.

• BTK degrader shows promising early data, with a head-to-head trial against pirtobrutinib underway; first approvals for Sonrotoclax expected in 2026 and BTK degrader in 2027.

• Emphasizes running phase III head-to-head trials versus standard of care to establish clear clinical and commercial differentiation.